Ramot, the technology transfer office of Tel Aviv University (TAU), has signed licensing agreements with US-based medical products supplier Baxter International with the aim of commercialising research.
The two will conduct joint research to evaluate a range of technologies currently being developed at the university and Tel Aviv Sourasky Medical Center. They will particularly focus on projects that tackle unmet clinical needs.
Under a first agreement, Baxter will exclusively license technology funded by Ramot’s early-stage investment vehicle TAU Technology Innovation Momentum Fund.
A second agreement will allow Baxter to license technology from Tel Aviv Sourasky Medical Center (TASMC).
Baxter will help commercialise early-stage research currently being developed at TAU and TASMC, in time expanding its product range into other areas of surgical care.
Shlomo Nimrodi, chief executive officer of Ramot, said: “TAU is world renowned as a leading academic and research institution for its innovation and entrepreneurship.
“We are gratified to see another one of TAU’s technologies graduating from our unique value enhancement program the TAU Technology Innovation Momentum Fund.
“We are happy to partner Baxter to explore how we can bring leading technologies to operating rooms worldwide.”
